Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial
Phase: PHASE3
Conditions: Fibromyalgia
Sponsor: Marius Henriksen

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
0 
 
 
 
CLINICAL TRIAL PROTOCOL 
 
 Cannabidiol for Fibromyalgia 
The CANNFIB trial 
Protocol for a randomized, double-blind, placebo-controlled, parallel-group, single-center trial 
 
 
Sponsor Investigator                                                                                                                                                       
Marianne Uggen Rasmussen (MUR) RN, MPH, PhD; Post-doctoral fellow 
Primary Investigator and Supervisor                                                                                                                                             
Kirstine Amris (KA) MD, DMSc; Senior Rheumatologist      
CO-investigator and statistical advisor                                                                                                                                       
Robin Christensen (RC) MSc, PhD; Professor of Biostatistics and Clinical Epidemiology 
CO-investigator and advisor 
Eva Ejlersen Wæhrens (EEW) OT, DMSc; Senior Researcher 
CO-investigator and advisor                                                                                                                                             
Henning Bliddal (HB) MD, DMSc; Professor of Rheumatology 
 
Sponsor contact details                                                                                                                                                  
Marianne Uggen Rasmussen                                                                                                                                                      
The Parker Institute, Bispebjerg and Frederiksberg Hospital,                                                                                       
Nordre Fasanvej 57,                                                                                                                                                                     
DK-2000 Frederiksberg                                                                                                                                                             
Phone: +45 38164197                                                                                                                                                                         
Email: marianne.uggen.rasmussen@regionh.dk 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
1 
 
 
LIST OF ABBREVIATIONS 
ACR 
American college of rheumatology 
ADL-Q Activities of daily living questionnaire 
AE 
Adverse events 
AMPS Assessment of Motor and Process Skills 
BIA  
Bioelectrical impedance analysis 
CBD 
Cannabidiol 
DASS     Depression anxiety and stress scale 
 
DUN 
Dispensing unit number 
EQ5D EuroQol Group self-rated health questionnaire 
FDA 
USA food and drug agency 
FIQ-R 
Fibromyalgia impact questionnaire-revised 
FPFV 
First patient first visit 
GCP  
Good clinical practice 
hCG 
Human chorionic gonadotropin 
ICMJE International Committee of Medial Journal Editors 
ITT 
Intention to treat 
LPFV 
Last patient first visit 
LPLV 
Last patient last visit 
NRS 
Numeric rating scale 
PROM Patient reported outcome measures 
PRP 
Patients Research Partners 
PSEQ 
Pain self-efficacy questionnaire 
PSQI 
Pittsburgh sleep quality index 
PSS        Perceived stress scale  
SAE 
Serious adverse events 
SNAQ Simplified Nutritional Appetite Questionnaire 
THC 
Delta-9-tetrahydrocannabinol 
WHR 
Waist-to-hip ratio 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
2 
 
CONTENT 
1 
PROTOCOL SYNOPSIS 
2 
INTRODUCTION 
2.1           Background 
2.2           Relevance of investigation 
3 
RATIONALE AND EVIDENCE TO DATE 
3.1            Medical cannabis 
3.2            Medical cannabis and fibromyalgia 
3.3            Rationale for trial 
4 
OBJECTIVES 
4.1            Primary objective 
4.2            Key secondary objectives 
4.3            Supportive secondary objectives 
4.4            Safety 
5 
HYPOTHESIS 
6 
STUDY PLAN 
6.1             Design 
6.2             Randomization and treatment allocation 
6.3             Site 
6.4             End of Trial 
7 
SUBJECT SELECTION 
7.1             Inclusion criteria 
7.2             Exclusion criteria 
7.3             Subject enrolment 
7.4             Baseline pregnancy test and contraception 
8 
INTERVENTIONS AND OBSERVATION  
8.1             Examinations and testing 
8.2             Pre-randomization screening period 
8.3             Drug intervention period 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
3 
 
8.4             Study drug use, content and handling 
8.5             Post-interventional observation period 
9 
ENDPOINTS 
9.1             Outcome measures 
9.2             Primary endpoints 
9.3             Key secondary endpoints 
9.4             Exploratory secondary endpoints  
10 STUDY PROCEDURES 
10.1 
Visit description 
10.2 
Visit schedule 
11 SAFETY CONSIDERATIONS 
11.1 
Potential side effects, risks and discomfort for study subjects 
11.2 
Adverse events 
12 STASTISTICAL CONSIDERATIONS 
12.1 
Power calculation 
12.2 
Statistical analyses 
13 DATA MANAGEMENT 
13.1 
Data handling 
13.2 
Data ownership 
14 SPONSORSHIP 
15 DISSEMINATION AND TRANSPARENCY 
15.1 
Registrations 
15.2 
Protocol publication and patient research partners 
15.3 
Publications and communication 
16 ETHICAL CONCIDERATIONS 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
4 
 
1. PROTOCOL SYNOPSIS 
Location 
 
The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg 
Hospital.                                                                                                                                            
 
 
Title 
  
Medical cannabis for fibromyalgia. 
 
 
Design  
 
A randomized, double-blind, placebo-controlled, parallel-group, single-center trial. 
 
 
Compound 
 
Medical cannabis; cannabidiol (CBD). 
 
 
Key dates 
 
First patient first visit: 4th quarter 2020.                                                                                  
Last patient first visit: 
4th quarter 2021.                                                                                  
Last patient last visit: 
3rd quarter 2022. 
 
 
Duration 
 
Trial duration is 40 weeks; including a up to four-week screening period (week -4 to 
0), a 24-week main trial period (weeks 0 to 24), and a 12-week post-intervention 
observation period (weeks 24 to 36). 
 
 
Participants 
 
Patients fulfilling the 1990 ACR-criteria for Fibromyalgia above 18 years of age. 
 
 
Sample size 
 
200 patients. 
 
 
Objectives 
 
To establish the efficacy of cannabidiol compared to placebo after 24 weeks on pain 
intensity, and other relevant outcomes including sleep quality, sleep duration, 
activities of daily living, quality of life, and energy level. 
 
Safety  
To monitor the safety and tolerability of cannabidiol use over 24 weeks in patients 
with fibromyalgia. 
 
 
Procedures 
 
Patients will be randomized to receive either cannabidiol (CBD) 50 mg, or an 
identically appearing cannabidiol - placebo daily, after a 4-week screening period 
prior to randomization. 
 
 
End points     
Primary endpoint is change in pain intensity on a Numeric Rating Scale 0-10 from 
week 0 to week 24. Key secondary outcomes are changes in sleep quality, sleep 
duration, activities of daily living and quality of life from week 0 to week 24. 
 
 
 
Supportive (exploratory) secondary objectives include changes in sleep latency, pain 
self-efficacy, stiffness, energy level, physical activity, feeling rested, depression, 
anxiety, stress, memory problems, tenderness, balance problems, environmental 
sensitivity, pressure pain threshold and tolerance, muscle fatiguability, appetite, 
body weight, body composition and pain reduction 30% and 50% from week 0 to 
week 24. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
5 
 
2. INTRODUCTION 
2.1. Background 
Fibromyalgia is a serious chronic pain condition affecting 2-5 % of the background population, according to 
European studies [1–3]. The disease burden in most affected individuals is substantial; the typical patient 
presenting with widespread musculoskeletal pain, high pain intensity, few pain-free intervals, and often the 
pain is accompanied by sleep disturbances, fatigue, cognitive dysfunction, and considerable emotional 
distress [4–6]. Fibromyalgia is strongly associated with disability and muscle fatigue [7], affecting daily life 
activities [8], leading to poor social participation and incapacity for normal employment which incurs high 
direct medical costs as well as significant indirect costs, e.g. sick leave and disability compensation [9]. 
Studies have shown that a substantial number of patients, are not satisfied with the treatments offered, and 
rate their health and quality of life after treatment as poor [9,10]. 
Recognizing, that there currently is no cure for fibromyalgia, symptom-based management aiming 
at symptom reduction and maintenance of optimal functioning is recommended by most clinical guidelines, 
and ideally management should include both non-pharmacological and pharmacological treatment 
strategies [11]. All recommendations for the pharmacological treatment of fibromyalgia now propose 
classes of medications, such as antidepressants and anticonvulsants, which target central pain processing 
mechanisms [12–14]. Several of these drugs have been tested in controlled trials for their efficacy in 
fibromyalgia, and meta-analyses have been written on most of these interventions [15–21]. Generally, these 
meta-analyses have revealed that overall effect sizes are modest; a minority of patients will have substantial 
benefit (patient reported pain relief of 50% or greater), and more will have moderate benefit (patient 
reported pain relief of 30% or greater). Many will have no or minimal benefit or will discontinue because of 
adverse events. However, it appears that even moderate reductions in pain may lead to considerable 
increase in self-reported quality of life and other outcome domains in this specific patient population 
[22,23]. 
Medical cannabis is popularly advocated for in Denmark, both among politicians and in the general 
population [24], for different health conditions including chronic pain. However, no evidence exists on what 
types of medical cannabis to use and what dosages to prescribe for the different conditions. In addition, 
safety issues such as adverse events and serious adverse events remain underexplored. Thus, physicians are 
reluctant to prescribe medical cannabis to their patients. Nevertheless, patients living with chronic pain are 
known to self-administer unlicensed medical cannabis. The extent of actual cannabis use is unknown, 
although, one study has documented that 13% of patients with fibromyalgia use cannabis regularly with a 
more extensive use among male patients compared to females [23]. Numbers from a Danish context show 
that only 17 out of 286 (6%), patients with fibromyalgia participating in a multidisciplinary rehabilitation 
program in Bispebjerg and Frederiksberg hospital during 2018, stated that they were using self-
administrated cannabis on a regular basis (unpublished data). Since self-administrated off-label use of 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
6 
 
cannabis is illegal in Denmark, this number may well be underreported. Still, individuals diagnosed with 
fibromyalgia who do admit to cannabis use, are sharing stories with health professionals about how 
unlicensed cannabis has improved their coping with everyday life, functional ability, pain, sleep, fatigue, 
mood and overall health related quality of life. Such compelling stories of individuals cannot be ignored and 
underline the necessity of exploring the efficacy of medical cannabis in a proper research design (i.e. with 
good internal validity). 
2.2. Relevance of investigation  
The use of the cannabis plant for medical purposes is limited in Europe. The European addiction societies 
stresses the need for further studies on the efficacy of medical cannabis and warrants for possible dangers 
associated with the increasing popularity of medical cannabis. Regulations are lacking concerning 
registration and medical indications, as well as the development of uniform compounds with regard to 
strength and types of products and rules concerning sales and marketing [25]. 
In Denmark, production and distribution of medical cannabis is illegal. However, starting from January 1st, 
2018, a four year pilot scheme has been legalized and approved by the Danish Medicines Agency [26], 
allowing for medical cannabis in the treatment of conditions such as multiple sclerosis, spinal injuries and 
nausea after chemotherapy and neuropathic pain. Although patients suffering from fibromyalgia have few 
treatment options for management of their disabling condition, this group is not included in the pilot 
scheme. However, under the pilot scheme, it is legal for physicians to prescribe cannabis for this and other 
patient groups. 
3. RATIONALE AND EVIDENCE TO DATE 
3.1. Medical cannabis 
Medical cannabis is the term for medications derived from dried cannabis plants in the form of capsules, 
pills or extracts/oils. The top shoot of the plant contains 100 cannabinoids that are divided into two 
subgroups; Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), affecting the CB1 receptors located 
in the central nervous system, and CB2 cannabinoid receptors located outside of the central nervous system 
[27]. While the TCH cannabinoids have psychoactive, appetite stimulating and nausea reducing effects, 
cannabidiol has anti-inflammatory, anti-convulsive and immune modulating effects [28]. Studies are 
inconclusive with regard to the effect of cannabidiol on appetite and food intake [29] Cannabinoids are 
known to be highly lipophilic and to accumulate in fatty tissue, and may influence the metabolism, fat 
distribution and accumulation in users [30]. It has been implicated that both TCH and CBD have pain 
reducing effects [31,32]. CBD is confirmed to have a favorable safety profile compared to THC [29]. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
7 
 
The US Food and Drug Administration (FDA), has recently approved Epydiolex® as the first 
prescription cannabis drug derived from the cannabis plant, for treating rare and severe forms of epilepsy 
[33]. Synthetically manufactured cannabis such as dronabinol (USA) [34] and nabilone (USA and UK), have 
been approved earlier in the treatment of nausea after chemotherapy [35]. The only synthetic cannabis 
based approved drug in Denmark is Sativex® for the treatment of multiple sclerosis [36]. However, none of 
the synthetic cannabis drugs are currently approved for the treatment of chronic pain conditions. 
3.2. Medical cannabis and fibromyalgia 
Evidence is sparse on medical cannabis in the treatment of fibromyalgia. In a Cochrane review on herbal 
cannabis (hashish, marihuana), plant-based and synthetic cannabinoids for fibromyalgia, only two out of 
four identified studies on the topic were included, due to small sample sizes, short-term duration and poor 
reporting of the other studies. The two studies were both on synthetic cannabinoid (nabilone). No high-
quality studies on plant-based cannabis could be identified. Evidence for efficacy was inconsistent as one 
study favored nabilone on pain and quality of life, compared to placebo, and the other study favored 
nabilone on sleep compared to Amitriptyline (anti-depressant). However, the quality of the studies was low 
and tolerability was low due to adverse events [37].  
Recent systematic reviews, have investigated the existing evidence on the effectiveness of 
cannabinoids for chronic non-cancer pain, including fibromyalgia. No impact on physical and emotional 
functioning was found, and only low-quality evidence found improved sleep and patient global impression 
of change. Thus, it was concluded to be unlikely that cannabinoids are effective in the treatment of non-
cancer pain [38], as findings were inconsistent for the effect of medical cannabis for fibromyalgia [39]. 
Surveys however, have showed favorable effect on fibromyalgia symptoms and health-related quality of life 
[40], and improved pain management and sleep, among users of  unlicensed  cannabis compared to non-
users [41], although no information on type and dosages of cannabis was given in the surveys. Negative 
patients’ perspectives themes such as the high cost, the negative effects of cannabis and the “views of 
others”, including their health care professionals, were also identified [41]. A recent retrospective study 
showed significantly favorable outcomes on fibromyalgia symptoms among medical cannabis users, and 
only mild adverse events. However, the retrospective design, the relatively small sample size and short 
duration reduced the quality of the study [42].  
3.3. Rationale for a randomized trial 
Based on the high demand and an increasing popularity of medical cannabis - which is currently used 
unlicensed among many patients with fibromyalgia, despite the lack of high-quality evidence on efficacy and 
safety, a well-designed randomized trial with a large sample size and clinically relevant duration is 
warranted. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
8 
 
4. OBJECTIVES 
The aim of this trial is to assess the efficacy and safety of cannabidiol use compared to placebo.  
4.1. Primary objective 
To assess the effect of cannabidiol 50 mg compared to cannabidiol-placebo, on change in pain intensity 
from baseline to week 24. 
4.2. Secondary (key) objectives 
To assess the effect of cannabidiol 50 mg, compared to cannabidiol-placebo, on changes in the following 
secondary key endpoints: 
• 
Sleep quality  
• 
Sleep duration 
• 
Activities of daily living  
• 
Quality of life  
4.3. Supportive (exploratory) secondary objectives 
For each group we will report changes in the following exploratory secondary endpoints:  
• 
Energy level  
• 
Sleep latency  
• 
Pain self-efficacy  
• 
Depression 
• 
Anxiety 
• 
Stress 
• 
Hair cortisol level 
• 
Stiffness 
• 
Feeling rested 
• 
Memory problems 
• 
Anxiety level 
• 
Tenderness (tenderness to touch) 
• 
Balance 
• 
Environmental sensitivity 
• 
Assessment of pressure pain threshold and tolerance 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
9 
 
• 
Assessment of muscle fatiguability 
• 
Appetite 
• 
Body weight  
• 
Body composition 
• 
Body fat distribution 
• 
Number of patients (in each group) with a 30 % and 50% reduction in pain intensity 
• 
To examine if observed ADL ability at baseline may predict treatment outcomes 
4.4. Safety 
To evaluate the safety and tolerability of cannabidiol 50 mg compared to cannabidiol 50 mg placebo in 
patients with fibromyalgia over 24 weeks. 
5. HYPOTHESES 
The primary hypothesis of the study is that pain intensity will be significantly reduced in participants 
receiving cannabidiol 50 mg compared to those receiving identically appearing placebo after 24 weeks. 
Secondary hypotheses are that sleep quality and duration, activities of daily living and quality of life, 
will be improved in participants receiving cannabidiol 50 mg compared to those receiving cannabidiol 50 mg 
placebo after 24 weeks. It is also hypothesized that participants receiving cannabidiol will improve on the 
supportive exploratory secondary outcomes, and that a higher proportion of those receiving cannabidiol will 
have a substantial benefit (50 % pain reduction) and a moderate benefit (30 % pain reduction). 
6. STUDY PLAN 
6.1. Design 
The trial is designed as a single-center, randomized, placebo-controlled, double blind and parallel-group 
trial.; the trial contains three periods: A pre-randomization screening period (week -8 to 0), a main trial 
period (week 0 to 24), and a post interventional observation period (week 24 to 36). The trial is designed to 
determine the efficacy and safety of cannabidiol use for patients with fibromyalgia, (see Figure 1). 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
10 
 
Figure 1: Illustration of the trial design 
The trial is scheduled to start inclusion of first patient first visit, primo November 2020 or as soon as 
possible thereafter, and the study period will go on for two year and end with the last patient last visit in 
September 2022. 
6.2. Randomization and treatment allocation 
Eligible participants, who are included at screening, will be randomized in a 1:1 manner to receive either 
cannabidiol 50 mg or placebo.  Allocation will also be stratified based on sex (male vs. female), age and pain 
intensity (over vs. under 7 on the FIQ-R pain numeric rating scale) to ensure that the two groups are as alike 
as possible. A computer-generated randomization sequence will create subject identification numbers and 
allocate the subjects to treatment arms. The subject number will be written on the medication label upon 
dispensation. This will ensure that participants receive the correct study drug or placebo according to 
treatment allocation. The randomization sequence will be created by an independent biostatistician using a 
random number generator (SAS Proc Plan), and subsequently entered in the electronic Case Report Form (e-
CRF), that will be developed specifically for the study, by an independent data manager. If unblinding of a 
participant is required due to an adverse event, the primary investigator can request to break the 
randomization code for the individual patient, via the independent data manager. The unblinding will 
always be performed at patient level and unblinding can take place any time during the day (24/7). 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
11 
 
Randomization and concealed allocation are done electronically in the e-CRF at the randomization visit 
(week 0).  
6.3. Site 
The study will be conducted at the Parker Institute, Bispebjerg and Frederiksberg Hospital, University of 
Copenhagen. The Parker Institute is a well-established research institute and clinical department with 
secretariat, data managers and Good Clinical Practice (GCP) trained health care professionals including 
physicians and study nurses. Monitoring will be conducted from the initiation and throughout the trial by 
the GCP unit at Bispebjerg and Frederiksberg hospital, in accordance with the GCP rules and regulations. 
6.4 End of trial 
The trial will end when the last patient has completed the last visit as well as the 12-week post 
interventional observation period, or prematurely discontinued the intervention or withdrawn from the 
trial, which comes last. 
7. PARTICIPANT SELECTION: ELIGIBILITY CRITERIA 
7.1. Inclusion criteria 
• 
Informed consent obtained 
• 
Clinical diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) 1990 
criteria [43] 
• 
Adult individuals (Age ≥18 years and <75 years) 
• 
Average pain intensity ≥ 4 on a Numeric Rating Scale (NRS) 
• 
No use of medical cannabis (THC/CBD) within the last six months 
• 
Proficiency in spoken Danish language and able to read and write in Danish 
7.2. Exclusion criteria 
• 
On-going participation in other medical trials for pain management of fibromyalgia 
• 
Diagnosis of Rheumatoid Arthritis or other inflammatory diseases 
• 
Diagnosis of other serious chronic diseases 
• 
Impaired liver and kidney function 
• 
Pregnancy or insufficient anti-conception therapy for fertile female participants 
• 
Planning pregnancy or insufficient anti-conception use in fertile female partners of male 
participants  

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
12 
 
• 
Breast feeding 
• 
Surgery scheduled for the trial period or within 3 months prior to enrollment 
• 
History of or current diagnosis of cancer 
• 
History of or current epilepsy and seizures 
• 
History of or major depressive disorder 
• 
History of a suicide attempt or any suicidal behavior 
• 
A mental state that may impede compliance with the program 
• 
History of severe psychiatric disorders 
• 
History of or current cannabis abuse  
• 
History of or current drug abuse 
• 
History of or current alcohol abuse 
• 
Severe personality disorder 
• 
Current use of opioids, opioid antagonists (LDN) or similar strong analgesics 
• 
Allergic reactions to the active ingredients in cannabidiol 
Participants who are using mild analgesics (e.g. NSAIDs, acetaminophen, paracetamol), on a regular or as-
needed (PRN) basis, may continue this treatment if needed during the study. Any changes in the 
participants concomitant medications will be monitored and documented. 
7.3. Participant enrolment 
Participants will be recruited from the multidisciplinary patient education and rehabilitation program of the 
fibromyalgia outpatient clinic at Bispebjerg and Frederiksberg hospital. Patients enrolled in this program 
have previously given their consent to be included in a national database (DanFib), and they have agreed to 
be contacted for the purpose of participation in potential studies and given permission for researchers to 
obtain relevant information regarding eligibility for studies, from the patients’ electronic hospital files 
(Sundhedsplatformen). Study recruitment will also be advertised on the Parker Institute website and the 
websites of the Danish Fibromyalgia Association and the Danish Rheumatism Association, and in the 
newspaper for Copenhagen metropolitan area. All potential trial participants who express an interest in the 
study, will be contacted by telephone by the study nurse, and given information about the purpose and the 
design of the trial. They will be informed that the design is placebo-controlled with two treatment arms, and 
that allocation to active treatment or placebo is random. Potential participants will also be asked a series of 
standardized questions to assess eligibility for study inclusion. At this point, potential participants who have 
not previously consented to this, will be asked if they approve that information from the patients’ electronic 
hospital files, may be obtained and disclosed to the investigators and study nurses, to assess their eligibility 
for study inclusion. Written information about the trial and mandatory information on study participants 
rights will be sent by mail or e-mail.  

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
13 
 
After a minimum of 24 hours after the potential participant has received oral and written 
information, a screening visit will be scheduled with the study physician (primary investigator or sub-
investigator) and the study nurse. If the participant wishes, they are welcome to bring a bystander to the 
screening visit. Study information is repeated without interruptions, in a private consultation with the study 
physician, to make sure that information is understood regarding the study aim, plan, visits, potential risks, 
adverse events, and complications. The participants will have the opportunity to ask questions and will be 
informed that they may have more time to consider their participation if needed, before informed consent 
is obtained and signed by the participant and the investigator. 
Participants are informed that by signing informed consent, they consent to allowing the 
investigators and controlling authorities direct access to the patients’ chart and electronic hospital files, to 
obtain study relevant information the such as medical history, laboratory results and medicinal history. This 
information is obtained to evaluate the efficacy of the project medicine and to ensure the safety and well-
being of the participants throughout the study. Participants are also informed that this information will be 
disclosed to the sponsor investigator, primary investigator, sub-investigators, and study nurses, as well as 
representatives from the independent monitoring organization: The GCP unit at Copenhagen University 
Hospital. The study will be performed in compliance with the Data Protection Act (Databeskyttelsesloven). 
 Participates will be informed that they may withdraw from the study at any time during the study, 
if they no longer wish to participate, and that they also can withdraw their informed consent. After the 
signed informed consent is obtained, inclusion and exclusion criteria are reviewed. Then a physical 
examination is performed, information regarding medical history and prior and concomitant medications is 
collected and blood samples are drawn. Patient Reported Outcome Measures (PROMs) are answered 
electronically on touch screens and transferred into the e-CRF. There will be no remuneration given to trial 
participants. 
7.4. Baseline pregnancy test and contraception 
Females of childbearing potential will have a urine pregnancy test (hCG) performed at the screening visit. 
This will not be required for menopausal women who have been without menstrual period for at least 1 
year. A negative pregnancy test is required for females of childbearing potential to be included in the study. 
Fertile women must use highly effective birth control methods during the entire period of the trial, unless 
their partner is vasectomized or in the case of sexual abstinence. Highly effective methods include hormonal 
contraception (birth control pills, intravaginal or transdermal patch or injection), intrauterine device (IUD), 
and intrauterine hormone-releasing system (IUS). Fertile male participants should use condom during the 
entire period of the trial. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
14 
 
 In the event of subjects becoming pregnant during the trial, they are instructed to notify the investigator 
immediately.  If a partner of a male participant becomes pregnant, the investigator should be notified 
immediately. 
8.INTERVENTIONS AND OBSERVATION 
8.1 Examinations and testing  
Participants will be subjected to a variety of examinations, questionnaires and testing during screening, 
enrolment and allocation, medical intervention visits, end of treatment and end of trial visits, (see table 1; 
visit schedule). Blood testing with standard biochemistry (C-reactive protein, Alanine Aminotransferase, 
Alkaline phosphatases, bilirubin, calcium, creatinine, potassium, sodium and hematology (hemoglobin, 
leucocytes, differential cell count, erythrocyte, erythrocyte volume fraction, erythrocyte middle volume, 
erythrocyte middle cell hemoglobin concentration, thrombocytes, reticulocytes), will be performed at 
screening visit, week 12 and week 24. Blood samples are drawn in order to monitor participants’ liver and 
kidney function, inflammation markers and overall hematology, for safety. The sample will contain 10 ml of 
blood and will be destroyed after analysis. Urine samples for pregnancy tests and screening for Cannabinoid 
(THC) and opioid concentration in the urine, will be performed for safety and to ensure that participants are 
complying with the study protocol. The sample will contain 100 ml of urine and will be destroyed after 
analysis. Vital signs including blood pressure, systolic and diastolic and resting pulse (sitting down) will be 
monitored at all visits. ECG (12-lead) will be assessed at the screening visit. Participants will also undergo 
screening for potential psychiatric side effects including suicide risk, at the screening visit. 
8.2. Pre-randomization run-in-period 
After the screening visit, a pre-randomization run-in-period of up to 4 weeks starts (week -4 to 0), to ensure 
that potential participants fulfill all the inclusion criteria and have none of the exclusion criteria. Participants 
may continue with other prior medications for their pain if they wish (except for opioids). 
8.3. Drug intervention period 
Eligible participants will be randomly assigned 1:1 to receive cannabidiol 50 mg or an identically appearing 
placebo. All participants (independent of group) will be titrated up to 50 mg following a dose escalation 
scheme: Initial dosage of 10 mg daily (week 0), escalated every third day by 10 mg up to week 2. 
Subsequently participants will stay on 50 mg dosage until the week 24 end of treatment visit. Visits will be 
conducted weekly during the up-titration period (week 0, 1 and 2), and subsequent visits will take place at 
week 4, 8, 12, 16, 20 and 24, (see figure 1, Trial design and table 1. Visit schedule). Visits 1, 8 and 16 will be 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
15 
 
performed as a telephone visit. Medical monitoring of vital signs and clinical and laboratory evidence of 
potential adverse events will be conducted throughout the study. 
8.4. Study drug use, content and handling 
Cannabidiol will be administrated to the participants orally in tablet form.  Participants will start with 10 mg 
daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after 
two weeks). Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, 
then delayed increments are allowed. Subjects will be maintained at the highest tolerated dose level. 
However, reduction of the achieved maintenance level will lead to study discontinuation. The dosage of 50 
mg as the daily intake during the study period, is decided based on clinical experience from private pain 
clinics from where medical cannabis is prescribed in Denmark (Clinic Horsted), and on dialogue with the 
pharmacists at Glostrup pharmacy, who will supply the investigational medicinal product and placebo. 
Glostrup pharmacy is experienced in producing cannabidiol pills for research purposes, and “cannabidiol” 
placebo pills that are identical in appearance, taste, and smell. Glostrup pharmacy will be responsible for 
the labelling of the cannabidiol and placebo tablet packages with a unique Dispensing Unit Number (DUN). 
The investigating site will ensure proper storage of the trial products, in a locked and secure temperature-
controlled room. A non-blinded, non-investigator will ensure that participants are receiving the study drug 
or placebo according to the treatment allocation by parring DUN numbers and the recipient patient 
numbers in the e-CRF system. One investigator will be responsible for drug accountability. For each patient 
treated, the DUN number of the package will be documented, and the patients will be asked to return the 
empty packages after use for accountability. Proper destruction of unused drugs will be ensured. 
8.5 Post-interventional observation period 
After the termination of treatment, a post-interventional observational period of 12 weeks will be initiated. 
This period is essential for the assessment and monitoring of the effects of drug cessation on pain, sleep 
quality, pain self-efficacy, activities of daily Living, quality of life and the overall burden of fibromyalgia 
symptoms, as well as potential adverse events. 
9. ENDPOINTS 
Endpoints are selected based on the fibromyalgia core domains, identified by the OMERACT 9 (Outcome 
measures in Rheumatology) initiative [44].  
9.1 Outcome measures 
The following validated Patient Reported Outcomes (PRO’s) are applied in this study:  

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
16 
 
• 
The Fibromyalgia Impact Questionnaire Revised (FIQ-R) [45] 
• 
The Pittsburgh Sleep Quality Index (PSQI) [46]       
• 
The EuroQol Group Self-Rated Health Questionnaire (EQ5D) [47]  
• 
The Activities of Daily Living Questionnaire ADL-Q [48]    
• 
The Pain Self-Efficacy Questionnaire (PSEQ) [49,50]   
• 
The Depression, Anxiety, Stress Scale (DASS-21)[51]  
• 
The Perceived Stress Scale (PSS)[52] 
• 
Columbia-Suicide Severity Rating Scale (C-SSRS) [53]   
• 
The Simplified Nutritional Appetite Questionnaire (SNAQ) [54]  
• 
The Fibromyalgia Sensory Hypersensitivity Scale (FSHSS) [Developed at the Parker Institute] 
In addition, a basic information questionnaire will be applied at the screening visit to collect data on 
demography, medical and medication history.  
Observation-based outcomes are also applied in the study. The Assessment of Motor and process skills 
(AMPS) [55], is an observation-based, standardized evaluation of the individual’s ability to perform and 
complete activities of daily living. The AMPS motor ability measure reflects the level of effort, fatigability 
and clumsiness observed during performance of a task, whereas the AMPS process ability measure reflect 
how timely and well organized the tasks are performed [55]. Assessment of pressure pain threshold and 
tolerance is performed using computerized cuff pressure algometry [56]. Pain threshold is defined as the 
pressure of the cuff at the subjects first sensation of pain when applying constantly rising pressure. Pain 
tolerance is defined as the worst tolerable pain caused by the pressure stimulation and the pressure is 
switched off by the patient [56]. To assess muscle fatiguability, a static muscle exhaustion test is performed 
during which surface electromyography is recorded (non-invasively). From the surface electromyography 
signal, the degree of peripheral (muscular) and central (central nervous system) fatigue is quantified [7]. 
Hair clippings will be sampled from all participants and analyzed to assess cortisol contents as a biomarker 
for prolonged stress [57]. Objectively measured information on sleep and physical activity will be collected 
using the triaxial accelerometer device SENS MOTION® activity measurement system [58].Body weight (±0.1 
kg) will be measured using an electronic scale. To estimate body composition, bioimpedance measurement 
(BIA) will be conducted using the ImpediMed, model SFB7 [59], produced in Queensland, Australia, which 
measures impedance over a spectrum of frequencies. Waist and hip circumferences (WHR) will be 
measured using a tape measure to the nearest 0.1 cm, from which WHR will be calculated (waist 
circumference / hip circumference) are included as a measure of bodyfat distribution. 
9.2 Primary endpoint 
The primary endpoint is change in pain intensity from baseline to week 24, measured on a 0-10 Pain 
Numeric Rating scale (NRS) included in the FIQ-R. To facilitate interpretation of the pain intensity measure, 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
17 
 
the findings will also be communicated as the proportion of patients achieving more than 30% and 50% pain 
reduction on the FIQ-R Pain Numeric Rating scale. 
9.3 Key secondary endpoints  
1. Change in sleep quality: PSQI subjective sleep quality domain 
2. Change in sleep duration: PSQI, sleep duration domain 
3. Change in objectively measured sleep duration and patterns: accelerometer data 
4. Change in activities of daily living: AMPS and ADL-Q total 
5. Change in Quality of life: EQ5D total 
9.4 Exploratory secondary endpoints  
1. Change in sleep latency: PSQI, sleep latency domain  
2. Change in pain self-efficacy: PSEQ total  
3. Change in stiffness: FIQ-R stiffness subscale 
4. Change in energy level: FIQ-R energy subscale 
5. Change in objectively measured physical activity: accelerometer data  
6. Change in feeling rested: FIQ-R rested subscale  
7. Change in depression: FIQ-R depression subscale  
8. Change in depression, anxiety and stress: DASS depression anxiety and stress scale 
9. Change in anxiety level:  FIQ-R anxiety subscale  
10. Change in perceived stress: PSS perceived stress scale  
11. Change in cortisol concentration in hair: hair clipping analysis 
12. Change in memory problems: FIQ-R memory subscale  
13. Change in tenderness level (tenderness to touch): FIQ-R tenderness subscale  
14. Change in balance problems: FIQ balance subscale  
15. Change in environmental sensitivity: FIQ environmental sensitivity subscale and FSHSS 
16. Change in pressure pain threshold and tolerance: Cuff algometry 
17. Change in muscle fatiguability 
18. Change in appetite: SNAQ 
19. Change in body weight  
20. Change in body composition: BIA  
21. Change in body fat distribution: WHR 
 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
18 
 
10. STUDY PROCEDURES 
10.1 
Visit description 
Prescreening (week -8 to-4) 
• 
Exchange of oral information and general eligibility screening; done by telephone by study nurse or 
secretary 
• 
Written trial information material and information on trial subjects’ rights is sent to potential 
participants 
Screening visit (week -4 to 0) 
• 
Information about the trial and participants’ rights is repeated  
• 
Signed informed consent is obtained by the study physician (primary investigator or sub 
investigator) 
• 
Eligibility, inclusion and exclusion criteria are reviewed 
• 
Physical examination to assess for eligibility and ensure safety 
• 
Medical history 
• 
Medication history 
• 
Vital signs (blood pressure and pulse), body weight and height 
• 
Electrocardiogram (ECG 12-lead) 
• 
Blood testing for standard biochemistry and hematology (see section 8.1) 
• 
Urine test (pregnancy, opioids, cannabinoid (TSH))  
• 
Vital signs 
• 
Body weight 
• 
ECG 
• 
Accelerometer data 
• 
Adverse events 
Randomization (week 0) 
• 
Medical history 
• 
Medication history 
• 
PROMs 
• 
AMPS 
• 
Cuff Algometry 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
19 
 
• 
Muscle fatiguability 
• 
Vital signs 
• 
Body weight 
• 
Body composition (BIA) 
• 
Body fat distribution (WHR) 
• 
Hair cortisol level 
• 
Accelerometer data 
• 
Adverse events 
• 
Blinded allocation to cannabidiol 50 mg or placebo 
• 
Medicine dispense 
Drug intervention (week 0 to 24) 
Up titration period (week 2) and telephone visits (weeks 1, 8 and 16)  
• 
Adverse events 
• 
Compliance assessment 
• 
Accelerometer data 
• 
Vital signs (week 2) 
Follow-up visits (Week 4, 12 and 20) 
• 
PROMs 
• 
Vital signs 
• 
Body weight 
• 
Blood testing with standard biochemistry and hematology (week 12) 
• 
Urine test (pregnancy, opioids, cannabinoid (TSH)) (week 12) 
• 
Adverse events 
• 
Compliance assessment 
• 
Medicine handout  
End of trial (week 24) 
• 
Physical examination 
• 
PROMs 
• 
AMPS  
• 
Hair cortisol level 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
20 
 
• 
Cuff algometry 
• 
Muscle fatiguability 
• 
Vital signs 
• 
Blood testing with standard biochemistry and hematology 
• 
Urine test (pregnancy, opioids, cannabinoid (TSH)) 
• 
Body weight 
• 
Body composition (BIA) 
• 
Body fat distribution (WHR) 
• 
Accelerometer data (collection start one week prior to end of trial) 
• 
Adverse events 
• 
Compliance assessment 
 End of follow-up (week 36) 
• 
PROMs 
• 
Vital signs 
• 
Body weight 
• 
Adverse events 
 
 
 
 
 
 
 
 
 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
21 
 
10.2 Visit schedule 
* Visits to be performed via telephone call                                                                                                                        
Visit window is ± 7-days. 
 
 
Study phases 
Prescreening 
Screening 
Randomization 
 
 
Drug intervention 
End of trial 
End of follow-up 
 
 
 
Up-titration  
Follow-up visits 
 
 
Week no. 
-8 - -4 
-4 - 0 
0 
1* 
2 
4 
8* 
12 
16* 
20 
24 
36 
Information 
x 
x 
x 
 
 
 
 
 
 
 
 
 
Eligibility screening 
x 
x 
 
 
 
 
 
 
 
 
 
 
Informed consent 
 
x 
 
 
 
 
 
 
 
 
 
 
Physical examination 
 
x 
 
 
 
 
 
 
 
 
x 
 
Medical history 
 
x 
x 
 
 
 
 
 
 
 
 
 
Medication history 
 
x 
x 
 
 
 
 
 
 
 
 
 
Blood testing 
 
x 
 
 
 
 
 
x 
 
 
x 
 
Urine test 
 
x 
 
 
 
 
 
x 
 
 
x 
 
PROMs 
 
 
x 
 
 
x 
 
x 
 
x 
x 
x 
AMPS 
 
 
x 
 
 
 
 
 
 
 
x 
 
Cuff algometry 
 
 
x 
 
 
 
 
 
 
 
x 
 
Muscle fatiguability 
 
 
x 
 
 
 
 
 
 
 
x 
 
Vital signs (BP, pulse) 
 
x 
x 
 
x 
x 
 
x 
 
x 
x 
x 
Body weight 
 
x 
x 
 
 
x 
 
x 
 
x 
x 
x 
Body composition 
 
 
x 
 
 
 
 
 
 
 
x 
 
Body fat distribution 
 
 
x 
 
 
 
 
 
 
 
x 
 
Height 
 
x 
 
 
 
 
 
 
 
 
 
 
ECG (12-lead) 
 
x 
 
 
 
 
 
 
 
 
 
 
Hair clipping (Cortisol) 
 
 
x 
 
 
 
 
 
 
 
x 
 
Accelerometer data 
 
x 
x 
 
 
 
 
 
 
 
x 
 
Adverse events 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Medicine allocation 
 
 
x 
 
 
 
 
 
 
 
 
 
Medicine dispense 
 
 
x 
 
 
x 
 
x 
 
x 
 
 
Compliance 
assessment 
 
 
 
x 
x 
x 
x 
x 
x 
x 
x 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
22 
 
11. SAFETY CONSIDERATIONS 
11.1. Potential side effects, risks, and discomforts for study subjects 
Common side effects (1-10%) of drugs containing both THC and CBD (Sativex), are overall feeling of 
weakness and uneasiness, reduced or increased appetite, diarrhea, nausea, dryness in the mouth, 
constipation, apathy, balance problems, depression, euphoria, feeling of intoxication, problems with 
memory and concentration, confusion, personality disorders, sleepiness, difficulty speaking, blurred vision. 
Rare side effects (0,1-1%) are abdominal pain, hypertension, hallucinations, psychosis, suicidal behavior and 
fainting. THC and CBD may interact with and enhance the effects of sedatives and alcohol [60]. According to 
the current legal practice in Denmark, it is not allowed to drive a car when using medical THC. CBD alone is 
shown to have a favorable safety profile compared to the CBD + THC combined or THC alone.   
The most commonly reported side effects of CBD (seen in at least 10%), are tiredness/fatigue, 
problems sleeping, feeling weak, changes in appetite and weight, infections, diarrhea and rash [61].  More 
serious and rare side effects (seen in at least 1 %), are hypersensitivity reactions, hepatocellular injury and 
suicidal behavior and ideation [62]. However, these serious side effect have been reported in patients 
diagnosed with epilepsy who have been undergoing treatment with daily Cannabidiol dosages of 5 mg per 
kilogram body weight [62], which could be six times the dosages prescribed in the current CANNFIB study. 
11.2 Adverse events 
Potential adverse events (AE) will be assessed for at every visit throughout the study, and all evidence of a 
clinical and/or laboratory AE will be documented in the patient’s medical file and recorded in the patient e-
CRF. The primary investigator or sub investigator will assess the seriousness of the AE and the probability of 
the AE being related to the study drug. Subsequently the AE will be followed up on its duration and whether 
it is resolving or not to a satisfactory conclusion, and any concomitant medication taken in relation to the 
AE, will be recorded in the patient’s medical file and. All adverse events will be documented from the start 
of the study drug administration to 12 weeks after the discontinuation of the study drug. 
The Parker Institute as the investigator of the study, will be responsible for the reporting of all 
Serious Adverse Events (SAE), which is defined as an AE resulting in death, being life-threatening, requiring 
hospitalization or resulting in significant disability. If a SAE occur, the investigator will report it within 24 
hours of the site being made aware of the SAE, to the sponsor. The Parker Institute will as the sponsor of 
the study, be responsible for the reporting of any deadly or life-threatening Suspected Unexpected Serious 
Adverse Reactions (SUSARS) that may occur, to the Danish Medicines Agency, as soon as possible and no 
later than 7 days after being made aware of the SUSAR. The Parker Institute will also be responsible for 
reporting any additional information regarding the SUSAR, within 8 days of the initial reporting. The Parker 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
23 
 
Institute will be responsible to report any other SUSARs to the Danish Medicines Agency within 15 days 
after being made aware of the SUSAR. 
The Reference document to be used to assess whether a reported SAE is suspected or unexpected, is the 
product resume of Epidyolex in which the active ingredient is Cannabidiol [63].  
12. STATISTICAL CONSIDERATIONS 
12.1 Sample size and Power considerations 
For a two-sample pooled t-test of a normal mean difference with a two-sided significance level of 0.05 
(p<0.05), assuming a common standard deviation of 2 on a 0-10 pain numeric rating scale, a total sample 
size of 200 assuming a balanced design (1:1), will have the statistical power of 0.94 (94%) to detect a 
difference between the means of 6 and 7. Even with a smaller sample of 128 patients assuming a balanced 
design (1:1), the statistical power of the required 80 % will be obtained, to detect a difference between of 1 
on a 0-10 pain numeric rating scale. 
12.2 Statistical analyses 
The details for the statistical analyses plan (SAP) will be determined prior to the completion of data 
collection and before the data analyses are initiated [64]. The prespecified efficacy analyses will be based on 
the data for full analysis set; the intention-to-treat (ITT) population, which includes all participants that are 
assessed and randomized at baseline. In the case of missing data at week 24, the baseline values will be 
carried forward and included in the of trial analyses. 
The primary analyses will be the comparison between cannabidiol 50 mg and placebo, using a mixed 
linear repeated-measures ANCOVA model with treatment, stratifying factors, and weeks from baseline as 
fixed effects; in order to reduce the random variation, we will adjustment for the level at baseline as a 
covariate. From this model the potential observed differences in pain intensity (FIQ-R NRS) and the 
secondary continuous outcomes will be estimated together with the associate 95% confidence interval and 
the p-value corresponding to the test of the hypotheses of no difference between treatments (i.e. the null 
hypothesis). 
To establish the efficacy of cannabidiol 50 mg compared to placebo in patients with fibromyalgia, 
the key secondary endpoints are tested in a hierarchical manner in the order in which endpoints are 
presented. Cannabidiol will be considered statically significantly better than placebo with respect to change 
in pain intensity FIQ-R NRS if the null hypothesis is rejected (p<0.05). Categorical changes for dichotomous 
end points will be analyzed with the use of logistic regression with the same fixed effects and covariates as 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
24 
 
the respective ANCOVA for continuous outcomes (see above). Sensitivity analyses will be performed to 
assess the robustness for the primary analyses, including a ‘non-responder imputation’, ‘multiple 
imputation techniques ‘, and a ‘per protocol analysis’.  
The SAP will also include explicit details on how we will handle/adjust for multiplicity: Multiplicity, as a 
consequence of many secondary outcome comparisons in the clinical trial, increases the likelihood that a 
chance association could be deemed causal. This problem commonly arises in clinical trials that have several 
clinical objectives based on the evaluation of multiple end points. In this trial, P values will be narratively 
adjusted for the key secondary outcomes (e.g., Bonferroni adjustments). 
13. DATA MANAGEMENT 
13.1 Data handling 
The collection, preservation and dissemination of the clinical data abide to the standard requirements for 
GCP-compliant data management in clinical trials. Before commencement of any clinical activity, approval 
from the Danish Medicines Agency, The Regional Health Research Ethics Committees for the Capital Region 
(De Videnskabsetiske Komiteer for Region Hovedstaden) and the National Data Protection Agency, will be 
obtained. A secure database will be established for the collection of clinical data via the e-CRF platform 
through a secure connection at the clinical research facility. All data obtained during the study will be 
documented in the individual eCRF. In the case of missing data, the reasons for this will be noted in the e-
CRF. 
Participant information collected in the e-CRF but not recorded in the patient files, will be regarded 
as source data. However, the patients’ participation and any SAE related to the study treatment will be 
documented in the patient hospital files. No patient information such as medical history and medication 
history will be collected from the patient hospital files, before informed consent has been obtained from 
the patient.  
Information obtained directly from potential participators prior to obtained signed informed 
consent (i.e. during the telephone eligibility screening), will be recorded in the e-CFR, and this information 
will be made available to the researchers, upon permission from the patients. 
In the process of ensuring data completeness and accuracy, source data verification (SDV), will be 
performed. The patients will be informed in writing about the need for SDV. The GCP-unit, investigators, 
sponsors and study coordinators will perform SDV, after informed consent is obtained, and require the 
following data to get information about the subjects’ health condition from the patients’ electronic hospital 
files (Sundhedsplatformen): Admission to hospital for any reason including diagnoses, surgical procedures, 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
25 
 
medical history and medication history. SDV will be performed as a required part of the project not only to 
get information about the subjects’ health condition, but also for the required control purposes, including 
site self-monitoring, quality control and GCP- monitoring. The dissemination of relevant information from 
patient files will be conducted in accordance with the Danish health act § 46. Data collection may continue 
for participants who wish to stop the intake of the study drug or discontinue from the study for other 
reasons, and these participants will be invited to attend the end-of-trial and follow-up, unless they have 
withdrawn their informed consent. 
The Parker Institute will ensure adherence to the EU-wide data protection instrument, the General 
Data Protection Regulation, ("the Regulation"), of May 25th, 2018. Consequently, all data will be handled in 
alignment with the following principles: 
• 
Personal data is fairly and lawfully processed 
• 
It is processed for limited and specified purposes 
• 
Data collection is adequate, relevant and not excessive 
• 
Data are kept accurate and up to date 
• 
Personal data are not kept longer than necessary 
• 
The data are processed in line with subjects’ rights 
• 
All reasonable measures are used to ensure data projection 
• 
Data is not transferred to other countries without adequate protection 
• 
An internal project handling process will ensure that the technical procedure for delivering data and 
the legal procedure for permitting data delivery are handled separately 
• 
All software installations are kept under surveillance for security related updates 
• 
Staff having data-handling task are governed by strict rules for known security breaches 
• 
Decoded data will only be delivered under written signed security-instructions and will normally be 
delivered without possibility to identify the person 
• 
Participants have a right to get insight in their own personal data 
13.2 Data ownership 
All data obtained during this study belongs to the Parker institute. All investigators will have full access 
(except for the described blinding) to all data before, during and up to 10 years after the study is completed. 
 
 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
26 
 
14. SPONSORSHIP 
The CannFib trial is a sponsor/investigator-initiated trial, initiated by Marianne Uggen Rasmussen (Sponsor 
Investigator), in close cooperation with Kirstine Amris (Primary Investigator) and the Parker Institute, thus, 
the status of the sponsor is non-commercial. The trial has received a grant from the Danish Rheumatism 
Association (Gigtforeningen) of 285.000 DKK, and additional grants have been given from The Erna Hamilton 
Foundation: 100.000 DKK, The Aase and Ejnar Danielsen’s foundation: 100.000 DKK and an internal research 
grant from the Copenhagen University Hospital, Bispebjerg and Frederiksberg: 100.000 DKK. In addition, the 
project investigational medicinal product will be partly sponsored with 600.000 DKK by Nordic Cannabis 
Research, and Linnea Switzerland who are supplying the plant-based cannabidiol for production to Glostrup 
pharmacy. 
Financial support to cover for study operational costs including study medicine and placebo as well 
as the salary of the researcher, are applied for from various external grants, that will be transferred to the 
Parker Institute. The Regional Health Research Ethics Committees for the Capital Region and the study 
participants will be notified if future financial support is granted. The overall study expenses in Danish 
kroner, are estimated to be the following: 
 
 
 
 
 
 
 
 
 
If external funding is not obtained to cover all the expenses, the Parker Institute will cover all excess 
costs of the study. The Parker Institute, Bispebjerg and Frederiksberg Hospital is supported by a core grant 
• 
Cannabidiol 50 mg and cannabidiol 50 mg placebo: 
    
885.000 
• 
Salary sponsor investigator (nurse) 2 years:     
  
800.000 
• 
Clinical examinations                                  
                   
200.000 
• 
Hair cortisol analyses                                                                    
100.000 
• 
Lab technician  
 
 
 
 
    
140.000 
• 
Occupational therapist (AMPS tests)                                              
140.000 
• 
Hair cortisol measurements                                                        
180.000 
• 
Accelerometers                                                                               
  40.000 
• 
Database assistance                                                                       
30.000 
• 
Statistical advisor                                                                            
25.000 
• 
Cuff algometry  
 
 
 
                    
75.000 
• 
Publication expenses 
 
 
 
 
 
     20.000 
• 
Total budget                                                                               
2.635.000 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
27 
 
from the Oak Foundation (OCAY-13-309). Neither Marianne Uggen Rasmussen or any other member of the 
project group has financial interest in the conduct of the trial or the results of the trial. 
15. DISSEMINATION AND TRANSPARENCY 
15.1 Registrations 
The trial will be subject to registration according to the specifications from the International Committee of 
Medial Journal Editors (ICMJE), and the trial will be uploaded and registered at ClinicalTrials.gov prior to 
patient enrolment. A notification will be submitted to the national authorities before commencement of the 
trial as applicable according to the Danish Medicines Agency. The sponsor will apply for permission to 
conduct the trial from the Danish Medicines Agency, the national committee on health research ethics as 
well as the local data protection agency. 
 
15.2 Protocol publication and patient research partners  
 
The full protocol will be published and will be freely available in open access. This project follows the EULAR 
recommendations [65] for the inclusion of patient representatives in the contemporary scientific process. 
Thus, the study is designed with the assistance of two Danish patient research partners (PRPs) of the Parker 
Institute; (Trine Leth [TL] and Elena Andersen [EA]. The two PRPs have participated in the process of 
designing and acknowledging the protocol in its current form. Collaboration between patients and health 
care professionals is developing and disseminating in the planning of research projects, to ensure that 
patient perspectives are fully taken into consideration in the trial and to ensure external validity.  
The results of the study will be submitted into EudraCT and thereby published on clinicaltrialregister.eu. 
 
15.3 Publications and communication 
Several manuscripts will be prepared for publication in scientific journals, starting with the protocol article. 
At the end of the trial the main article based on this protocol, will be prepared for publication in a high 
impact scientific journal. Subsequently, other studies will be conducted based on the data collected and 
prepared for publication, including a paper on predictive factors for a positive outcome of the intake of 
cannabidiol, and a separate paper on safety and adverse events associated with long-term use of 
cannabidiol. Both potential positive and negative findings, as well as inconclusive results will be published in 
ClinicalTrials.gov and in scientific journals. In addition to the scientific communication planned, the project 
has already gained general interest and has been mentioned in the newspaper (Børsen) and on several 
Danish websites (Gigtforeningen.dk, Sundhedspolitisk tidsskrift.dk and Cannabis Danmark.dk). A television 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
28 
 
team from Denmark’s Radio (DR1), will follow the study throughout the project period until the results are 
available, as part of a planned documentary series on chronic pain and medical cannabis. 
16. ETHICAL CONCIDERATIONS 
Unlicensed medical cannabis is known to be self-administrated among patients suffering from fibromyalgia, 
despite the lack of evidence on efficacy and safety of long-term cannabis use in patient with chronic 
widespread pain. Therefore, it is highly warranted, to investigate the efficacy and safety of medical cannabis 
intake, in a proper controlled research design to obtain high quality evidence on the already ongoing 
medical cannabis use in patients with fibromyalgia. In this study, the efficacy and safety of cannabidiol 
intake, is assessed by comparing cannabidiol to identical “cannabidiol” placebo pills that contains no active 
ingredients, in a double-blinded randomized design. This trial  will be conducted in accordance with this 
protocol and applicable regulatory requirements, and the ethical criteria of the Helsinki declaration [66], to 
ensure the well-being of the participants of the trial. Cannabidiol has a low adverse event profile compared 
to other components of medical cannabis. However, throughout the study, participants will be monitored 
closely to make sure they are safe and with a minimum of discomforts. Patients will be made aware of their 
right to withdraw from the study, and that withdrawal will not affect their possibility to receive future 
treatment. Thus, the health, well-being and rights of the individual research subjects will take precedence 
over the study objective to generate evidence on efficacy and safety on cannabidiol use over time. 
However, once the study results are obtained and regardless of the outcomes, the evidence obtained will 
benefit all patients with fibromyalgia as results can be used in future guidelines and recommendations in 
the administration of medical cannabis in the treatment of fibromyalgia. As the study is investigator-
initiated, the sponsor and the site are the same, and there is no sponsor-site contract. The trial is covered by 
the patient compensation insurance as it is originating from the capital region of Copenhagen, Denmark. 
 
 
 
 
 
 
 
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
29 
 
Reference List 
 
 1.  Jones GT, Atzeni F, Beasley M, Fluss E, Sarzi-Puttini P, Macfarlane GJ (2015) The prevalence of 
fibromyalgia in the general population: a comparison of the American College of 
Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 67: 
568-575. 
 2.  Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F (2015) The Prevalence and Characteristics of 
Fibromyalgia in the 2012 National Health Interview Survey. PLoS One 10: e0138024. 
 3.  Wolfe F, Brahler E, Hinz A, Hauser W (2013) Fibromyalgia prevalence, somatic symptom reporting, and 
the dimensionality of polysymptomatic distress: results from a survey of the general 
population. Arthritis Care Res (Hoboken ) 65: 777-785. 
 4.  Smith HS, Harris R, Clauw D (2011) Fibromyalgia: an afferent processing disorder leading to a complex 
pain generalized syndrome. Pain Physician 14: E217-E245. 
 5.  Coster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A (2008) Chronic widespread 
musculoskeletal pain - a comparison of those who meet criteria for fibromyalgia and those 
who do not. Eur J Pain 12: 600-610. 
 6.  Hallberg LR, Carlsson SG (2000) Coping with fibromyalgia. A qualitative study. Scand J Caring Sci 14: 
29-36. 
 7.  Bandak E, Amris K, Bliddal H, Danneskiold-Samsoe B, Henriksen M (2013) Muscle fatigue in 
fibromyalgia is in the brain, not in the muscles: a case-control study of perceived versus 
objective muscle fatigue. Ann Rheum Dis 72: 963-966. 
 8.  Amris K, Waehrens EE, Jespersen A, Bliddal H, Danneskiold-Samsoe B (2011) Observation-based 
assessment of functional ability in patients with chronic widespread pain: a cross-sectional 
study. Pain 152: 2470-2476. 
 9.  Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006) Survey of chronic pain in Europe: 
prevalence, impact on daily life, and treatment. Eur J Pain 10: 287-333. 
 10.  Sjogren P, Ekholm O, Peuckmann V, Gronbaek M (2009) Epidemiology of chronic pain in Denmark: an 
update. Eur J Pain 13: 287-292. 
 11.  Sundhedsstyrelsen, Callesen H, von Bülow C, Birkefoss K, Rasmussen M (2018) Nationale kliniske 
retningslinjer for udredning og behandling samt rehabilitering af patienter med 
genrelaliserede smerter i bevægeapparatet. 
https://www.sst.dk/da/udgivelser/2018/~/media/82268C6BAF19461399C4FC8D1647DCC0.as
hx. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
30 
 
 12.  Ablin JN, Buskila D (2010) Emerging therapies for fibromyalgia: an update. Expert Opin Emerg Drugs 
15: 521-533. 
 13.  Hauser W, Walitt B, Fitzcharles MA, Sommer C (2014) Review of pharmacological therapies in 
fibromyalgia syndrome. Arthritis Res Ther 16: 201. 
 14.  Smith HS, Bracken D, Smith JM (2011) Pharmacotherapy for fibromyalgia. Front Pharmacol 2:17. doi: 
10.3389/fphar.2011.00017. eCollection;%2011.: 17. 
 15.  Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C (2012) The role of antidepressants in the 
management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 
26: 297-307. 
 16.  Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B (2013) Serotonin and noradrenaline reuptake 
inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev CD010292. 
 17.  Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ (2009) Pregabalin for acute and chronic pain in 
adults. Cochrane Database Syst Rev CD007076. 
 18.  Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ (2012) Amitriptyline for neuropathic pain and 
fibromyalgia in adults. Cochrane Database Syst Rev 12:CD008242. doi: 
10.1002/14651858.CD008242.pub2.: CD008242. 
 19.  Tort S, Urrutia G, Nishishinya MB, Walitt B (2012) Monoamine oxidase inhibitors (MAOIs) for 
fibromyalgia syndrome. Cochrane Database Syst Rev CD009807. 
 20.  Uceyler N, Sommer C, Walitt B, Hauser W (2013) Anticonvulsants for fibromyalgia. Cochrane Database 
Syst Rev CD010782. 
 21.  Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, Lunn MP, Hamunen K, Haanpaa M, Kalso 
EA (2013) Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane 
reviews. Cochrane Database Syst Rev CD010567. 
 22.  Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ (2010) Fibromyalgia: Moderate and 
substantial pain intensity reduction predicts improvement in other outcomes and substantial 
quality of life gain. Pain 149: 360-364. 
 23.  Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y (2012) Association of herbal cannabis use 
with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res 
(Hoboken ) 64: 1202-1208. 
 24.  Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic 
review of randomized trials. Br J Clin Pharmacol 72: 735-744. 
 25.  Bramness JG, Dom G, Gual A, Mann K, Wurst FM (2018) A Survey on the Medical Use of Cannabis in 
Europe: A Position Paper. Eur Addict Res 24: 201-205. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
31 
 
 26.  2018) Lov om forsøgsordning med medicinsk cannabis. 
https://www.retsinformation.dk/Forms/R0710.aspx?id=196748. 
 27.  Lu HC, Mackie K (2016) An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 79: 
516-525. 
 28.  Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: 
delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 
153: 199-215. 
 29.  Iffland K, Grotenhermen F (2017) An Update on Safety and Side Effects of Cannabidiol: A Review of 
Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res 2: 139-154. 
 30.  Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018) A Systematic Review on the Pharmacokinetics of 
Cannabidiol in Humans. Front Pharmacol 9:1365. doi: 10.3389/fphar.2018.01365. 
eCollection;%2018.: 1365. 
 31.  Morales P, Hernandez-Folgado L, Goya P, Jagerovic N (2016) Cannabinoid receptor 2 (CB2) agonists 
and antagonists: a patent update. Expert Opin Ther Pat 26: 843-856. 
 32.  Temple LM (2016) Medical marijuana and pain management. Dis Mon 62: 346-352. 
 33.  Wise J (2018) FDA approves its first cannabis based medicine. BMJ 361:k2827.: k2827. 
 34.  2017) Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions 
Containing Dronabinol [(-)-delta-9-transtetrahydrocannabinol (delta-9-THC)] in Schedule II. 
Interim final rule, with request for comments. Fed Regist 82: 14815-14820. 
 35.  2018) Nabilone. https://pubchem.ncbi.nlm.nih.gov/compound/Nabilone#section=Top. 
 36.  Bifulco M, Pisanti S (2015) Medicinal use of cannabis in Europe: the fact that more countries legalize 
the medicinal use of cannabis should not become an argument for unfettered and 
uncontrolled use. EMBO Rep 16: 130-132. 
 37.  Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W (2016) Cannabinoids for fibromyalgia. Cochrane 
Database Syst Rev 7:CD011694. doi: 10.1002/14651858.CD011694.pub2.: CD011694. 
 38.  Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, 
Degenhardt L (2018) Cannabis and cannabinoids for the treatment of people with chronic 
noncancer pain conditions: a systematic review and meta-analysis of controlled and 
observational studies. Pain 159: 1932-1954. 
 39.  Banerjee S, McCormack S Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical 
Effectiveness and Guidelines. Ottawa: CADTH; 2019 Jul. (CADTH rapid response report: 
summary with critical appraisal). 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
32 
 
 40.  Fiz J, Duran M, Capella D, Carbonell J, Farre M (2011) Cannabis use in patients with fibromyalgia: 
effect on symptoms relief and health-related quality of life. PLoS One 6: e18440. 
 41.  Piper BJ, Beals ML, Abess AT, Nichols SD, Martin MW, Cobb CM, DeKeuster RM (2017) Chronic pain 
patients' perspectives of medical cannabis. Pain 158: 1373-1379. 
 42.  Habib G, Artul S (2018) Medical Cannabis for the Treatment of Fibromyalgia. J Clin Rheumatol 24: 255-
258. 
 43.  Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, 
Abeles M, Clark P, . (1990) The American College of Rheumatology 1990 Criteria for the 
Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 
33: 160-172. 
 44.  Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, 
Mease PJ (2009) Content and criterion validity of the preliminary core dataset for clinical trials 
in fibromyalgia syndrome. J Rheumatol 36: 2330-2334. 
 45.  Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL (2009) The Revised Fibromyalgia Impact 
Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 11: R120. 
 46.  Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: 
a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213. 
 47.  1990) EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 16: 
199-208. 
 48.  Waehrens EE, Bliddal H, Danneskiold-Samsoe B, Lund H, Fisher AG (2012) Differences between 
questionnaire- and interview-based measures of activities of daily living (ADL) ability and their 
association with observed ADL ability in women with rheumatoid arthritis, knee osteoarthritis, 
and fibromyalgia. Scand J Rheumatol 41: 95-102. 
 49.  Nicholas MK (2007) The pain self-efficacy questionnaire: Taking pain into account. Eur J Pain 11: 153-
163. 
 50.  Rasmussen MU, Rydahl-Hansen S, Amris K, Samsoe BD, Mortensen EL (2016) The adaptation of a 
Danish version of the Pain Self-Efficacy Questionnaire: reliability and construct validity in a 
population of patients with fibromyalgia in Denmark. Scand J Caring Sci 30: 202-210. 
 51.  Henry JD, Crawford JR (2005) The short-form version of the Depression Anxiety Stress Scales (DASS-
21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol 44: 
227-239. 
 52.  Nielsen MG, Ornbol E, Vestergaard M, Bech P, Larsen FB, Lasgaard M, Christensen KS (2016) The 
construct validity of the Perceived Stress Scale. J Psychosom Res 84:22-30. doi: 
10.1016/j.jpsychores.2016.03.009. Epub;%2016 Mar 16.: 22-30. 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
33 
 
 53.  Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, 
Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: initial validity 
and internal consistency findings from three multisite studies with adolescents and adults. Am 
J Psychiatry 168: 1266-1277. 
 54.  Wilson MM, Thomas DR, Rubenstein LZ, Chibnall JT, Anderson S, Baxi A, Diebold MR, Morley JE (2005) 
Appetite assessment: simple appetite questionnaire predicts weight loss in community-
dwelling adults and nursing home residents. Am J Clin Nutr 82: 1074-1081. 
 55.  Fisher, A. G. (2010) Assessment of Motor and Process Skills: Development, Standardization, and 
Administration Manual. Fort Collins, Colorado: Three Star Press.  
 56.  Jespersen A, Dreyer L, Kendall S, Graven-Nielsen T, Arendt-Nielsen L, Bliddal H, Danneskiold-Samsoe B 
(2007) Computerized cuff pressure algometry: A new method to assess deep-tissue 
hypersensitivity in fibromyalgia. Pain 131: 57-62. 
 57.  Van Uum SH, Sauve B, Fraser LA, Morley-Forster P, Paul TL, Koren G (2008) Elevated content of 
cortisol in hair of patients with severe chronic pain: a novel biomarker for stress. Stress 11: 
483-488. 
 58.  Sens Motion (2020) Discrete Wearable Acticity Sensor for Healthcare and Research.  
 59.  ImpediMed, SFB7 (2020) ImpediMed.  
 60.  Pro.medicin Information til sundhedsfaglige (2018) Sativex. 
https://pro.medicin.dk/Medicin/Praeparater/6456. 
 61.  Iffland K, Grotenhermen F (2017) An Update on Safety and Side Effects of Cannabidiol: A Review of 
Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res 2: 139-154. 
 62.  Greenwich Biosciences I (2020) Epidiolex Highlights of Prescibing Information.  
 63.  [Anonymous] (2020) Epidyolex Summary of product charachteristics.  
 64.  Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, Williamson PR, Altman DG, Montgomery 
A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E (2017) Guidelines for the Content of 
Statistical Analysis Plans in Clinical Trials. JAMA %19;318: 2337-2343. 
 65.  de Wit MP, Berlo SE, Aanerud GJ, Aletaha D, Bijlsma JW, Croucher L, Da Silva JA, Glusing B, Gossec L, 
Hewlett S, Jongkees M, Magnusson D, Scholte-Voshaar M, Richards P, Ziegler C, Abma TA 
(2011) European League Against Rheumatism recommendations for the inclusion of patient 
representatives in scientific projects. Ann Rheum Dis 70: 722-726. 
 66.  The Helsinki Declaration (2019)  Ethical Principles for Medical Reseach Involving Human Subjects.  
 

PROTOCOL: Cannabidiol for Fibromyalgia 
AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital 
DATE: 2020-12-14 
Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov 
Identifier: 
 
34